Clinical Trials Browser

Phase 1/2 × enasidenib × Other hematologic neoplasm × Clear all

NCT02677922 2026-02-19

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Phase 1/2 Active not recruiting

130 enrolled 38 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT04774393 2025-11-10

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05282459 2025-03-20

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Phase 1/2 Completed

Other hematologic neoplasm

Leukemia, Leukemia, Monocytic, Acute, Leukemia, Myeloid

NCT01915498 2024-10-22

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

Phase 1/2 Completed

345 enrolled 120 charts 1 FDA

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04092179 2024-01-24

ENAVEN-AML

Phase 1/2 Terminated

Other hematologic neoplasm

Neoplasms, Recurrence, Leukemia, Myeloid, Acute